| INDIANA UNIVERSITY RESEARCH AND TECHNOLOGY CORPORATION Patent applications |
| Patent application number | Title | Published |
|---|
| 20120100112 | MATERIALS AND METHODS FOR USING ADIPOSE STEM CELLS TO TREAT LUNG INJURY AND DISEASE - The present invention provides methods for treating patients with acute or chronic lung disease or injury to the lungs including injury caused by exposure to cigarette smoke other irritants or another cause of pulmonary distress. Typical conditions that can be treated include conditions that cause inflammation in the lung or the death of lung endothelial cells. Treatment of other conditions such as compromised bone marrow function and cachexia can also be treated by the inventive methods disclosed herein. These methods including contacting Adipose Stem Cells (ASC) or media conditioned by contact with ASC (ASC-CM) or various factors secreted by the same including the media or components of the media with lung tissue and cells. In some instances the ASC used is harvested from the patient's own adipose tissue while in other instances the source is an exogenous donor. | 04-26-2012 |
| 20120093776 | METHODS FOR TREATING DISEASES USING A BONE MORPHOGENETIC PROTEIN - Described herein are methods, uses, and pharmaceutical compositions for treating heart disease that include a bone morphogenetic protein (BMP). In addition, described herein are methods, uses, and compositions for preventing or slowing fibrosis in diseased or injured tissue, and/or for preventing or slowing cell death in diseased or injured tissue. | 04-19-2012 |
| 20120059305 | ARTERIOVENOUS SHUNT WITH INTEGRATED SURVEILLANCE SYSTEM - A hemodialytic angioacess device for implantation in dialysis patients, comprising an arteriovenous (AV) shunt, anastomotic valves that connect the AV shunt to blood vessels, a valve control system and an integrated surveillance system that measures flow conditions in the blood vessels at the AV shunt, preferably when the valves are closed and the patient is not undergoing dialysis treatment. The flow condition data, which may include data representing the flow rate, pressure, volume and velocity of blood flowing through the vessels, is stored in a memory and transmitted to a health care provider or technician on demand. The data can be used to calculate and monitor important physiological parameters, such as compliance and resistance, for the blood vessels, and help detect and identify dangerous conditions, such as turbulence and stasis, which can contribute to AV shunt failure, vessel injury and other serious complications for the patient. | 03-08-2012 |
| 20120011156 | INTER-CLASS MOLECULAR ASSOCIATION CONNECTIVITY MAPPING - Methods, systems, devices and/or apparatuses are provided for computationally deriving molecular association connectivity maps for the study of inter-class molecular associations in toxicogenomics and drug discovery applications. The inter-class molecular associations can be between at least one bio-molecular entity and at least one therapeutic agent. The methods, systems, devices and/or apparatuses apply integrated molecular interaction network mining and text mining techniques. | 01-12-2012 |
| 20110311453 | Alloyed semiconductor quantum dots and concentration-gradient alloyed quantum dots, series comprising the same and methods related thereto - An alloyed semiconductor quantum dot comprising an alloy of at least two semiconductors, wherein the quantum dot has a homogeneous composition and is characterized by a band gap energy that is non-linearly related to the molar ratio of the at least two semiconductors; a series of alloyed semiconductor quantum dots related thereto; a concentration-gradient quantum dot comprising an alloy of a first semiconductor and a second semiconductor, wherein the concentration of the first semiconductor gradually increases from the core of the quantum dot to the surface of the quantum dot and the concentration of the second semiconductor gradually decreases from the core of the quantum dot to the surface of the quantum dot; a series of concentration-gradient quantum dots related thereto; in vitro and in vivo methods of use; and methods of producing the alloyed semiconductor and concentration-gradient quantum dots and the series of quantum dots related thereto. | 12-22-2011 |
| 20110288003 | AMIDE BASED GLUCAGON AND SUPERFAMILY PEPTIDE PRODRUGS - Prodrug formulations of glucagon superfamily peptides are provided wherein the glucagon superfamily peptide has been modified by the linkage of a dipeptide to the glucagon superfamily through an amide bond linkage. The prodrugs disclosed herein have extended half lives and are converted to the active form at physiological conditions through a non-enzymatic reaction driven by chemical instability. | 11-24-2011 |
| 20110245164 | YL-BASED INSULIN-LIKE GROWTH FACTORS EXHIBITING HIGH ACTIVITY AT THE INSULIN RECEPTOR - Insulin-like growth factor analogs are disclosed wherein substitution of the IGF native amino acids, at positions corresponding to positions B16 and B17 of native insulin, with tyrosine and leucine, respectively, increases potency of the resulting analog at the insulin receptor by tenfold. Also disclosed are prodrug and depot formulations of the IGF analogs, wherein the IGF analog has been modified by the linkage of a dipeptide to the analog through an amide bond linkage. The prodrug and depot formulations disclosed herein have extended half lives of at least 2 hours, 10 hours, and more typically greater than 2 are converted to the active form at physiological conditions through a non-enzymatic reaction driven by chemical instability. | 10-06-2011 |
| 20110237493 | DIPEPTIDE LINKED MEDICINAL AGENTS - A non-enzymatically self cleaving dipeptide element is provided that can be linked to known medicinal agents via an amide bond. The dipeptide will spontaneously be cleaved from the medicinal agent under physiological conditions through a reaction driven by chemical instability. Accordingly, the dipeptide element provides a means of linking various compounds to known medicinal agents wherein the compounds are subsequently released from the medicinal agent after a predetermined time of exposure to physiological conditions. For example, the dipeptide can be linked to an active site of a drug to form a prodrug and/or the dipeptide may comprise a depot polymer to sequester an injectable composition comprising the complex at the point of administration. | 09-29-2011 |
| 20110217258 | Combined Use of Bendamustine, Doxorubicin and Bortezomib for the Treatment of Multiple Myeloma - Methods for treating multiple myeloma by administering a combination of a proteasome inhibitor, bendamustine and doxorubicin are described. | 09-08-2011 |
| 20110195510 | csPCNA Isoform Modifications And Uses Thereof - Methods and compositions to detect the presence of csPCNA isoform by identifying one or more posttranslational modifications are disclosed. Methods to identify csPCNA isoform through posttranslational modifications including methylesterification levels are disclosed. | 08-11-2011 |
| 20110183356 | METHOD TO IDENTIFY PATIENTS AT RISK FOR LUNG TRANSPLANT REJECTION - Various embodiments include methods for diagnosing and treating medical conditions that involve an autoimmune response to connective tissue such as collagen found in organs such as the lung. In one method pulmonary disease and disorders such as Idiopathic Pulmonary Fibrosis (IPF) are diagnosed by analyzing fluid or tissue samples obtained from a patient for evidence of an autoimmune response to various types of collagen including, for example, Type V. One type of assay for evidence of an autoimmune response to Type V collagen comprises the steps of obtaining a fluid or tissue sample from a patient, contacting at least a portion of the sample with antigen to anti-Type V collagen antibody and monitoring the mixture of sample and antigen for changes indicative of the presence of anti-Type V collagen in the sample. Another embodiment includes treating pulmonary diseases such as IPF by administering a therapeutically effective dose of epitopes of various collagens including Type V collagen. | 07-28-2011 |
| 20110166062 | GIP-BASED MIXED AGONISTS FOR TREATMENT OF METABOLIC DISORDERS AND OBESITY - Glucagon peptides that exhibit GIP agonist activity in addition to glucagon and/or GLP-I activity are provided. Pharmaceutical compositions comprising such glucagon peptides and therapeutic methods of using such peptides are also provided. | 07-07-2011 |
| 20110142846 | METHOD FOR DIAGNOSING AND TREATING EMPHYSEMA - The present invention provides methods for diagnosing a patient with emphysema or COPD by detecting the levels of EMAP II in a sample. Alternatively, methods are provided for determining the susceptibility of a patient to develop emphysema or COPD by detecting the levels of EMAP II in a sample. The levels of EMAP II may be determined by immunoassay techniques. The present invention also provides methods for treating patients with emphysema or COPD by administering a therapeutically effective amount of an EMAP II neutralizing compound. The compound may be an antibody, siRNA, antisense RNA or an antagonist of CXCR3. | 06-16-2011 |
| 20110098217 | COMPOUNDS EXHIBITING GLUCAGON ANTAGONIST AND GLP-1 AGONIST ACTIVITY - Glucagon analogs are disclosed that exhibit both glucagon antagonist and GLP-1 agonist activity. In one embodiment, the glucagon antagonist/GLP-1 agonist comprises a modified amino acid sequence of native glucagon, in which the first one to five N-terminal amino acids of native glucagon is deleted and in which the alpha helix is stabilized. | 04-28-2011 |
| 20110098188 | BLOOD BIOMARKERS FOR PSYCHOSIS - A plurality of biomarkers determine the diagnosis of psychosis based on the expression levels in a sample such as blood. Subsets of biomarkers predict the diagnosis of delusion or hallucination. The biomarkers are identified using a convergent functional genomics approach based on animal and human data. Methods and compositions for clinical diagnosis of psychosis are provided. | 04-28-2011 |
| 20110015386 | PERMETHYLATION OF OLIGOSACCHARIDES - A solid-phase permethylation procedure is described. For example, solid-phase permethylation can be utilized to prepare permethylated linear and branched, neutral and sialylated oligosaccharides, which can be analyzed by MALDI-MS. | 01-20-2011 |
| 20100331246 | ESTER-BASED INSULIN PRODRUGS - Prodrug formulations of bioactive polypeptides are provided wherein the bioactive polypeptide has been modified by the linkage of a dipeptide to the bioactive polypeptide through an ester linkage. The prodrugs disclosed herein in some embodiments have extended half lives of at least 1.5 hours (e.g., at least 10 hours), and more typically greater than 20 hours and less than 70 hours, and are converted to the active form at physiological conditions through a non-enzymatic reaction driven by chemical instability. | 12-30-2010 |
| 20100203058 | DIAGNOSTICS AND THERAPEUTICS BASED ON CIRCULATING PROGENITOR CELLS - Methods and compositions for detection, diagnosis, and therapeutics of arterial diseases based on pro-angiogenic and non-angiogenic circulating hematopoietic stem and progenitor cells (CHSPCs) and circulation endothelial colony forming cells (ECFCs) are described. | 08-12-2010 |
| 20100193678 | APPARATUS AND METHODS FOR ANALYZING IONS - An apparatus ( | 08-05-2010 |
| 20100190699 | GLUCAGON ANALOGS EXHIBITING ENHANCED SOLUBILITY IN PHYSIOLOGICAL pH BUFFERS - Modified glucagon peptides are disclosed having improved solubility while retaining glucagon agonist activity. The glycogen peptides have been modified by substitution of native amino acids with, and/or addition of, charged amino acids to the carboxy terminus of the peptide. The modified glucagon agonists can be further modified by pegylation, or the addition of a carboxy terminal peptide selected from the group consisting of SEQ ID NO: 20, SEQ ID NO: 21, SEQ ID NO: 23, or both to further enhance the solubility of the glucagon agonist analogs. | 07-29-2010 |
| 20100128221 | LASER SCANNING DIGITAL CAMERA WITH PUPIL PERIPHERY ILLUMINATION AND POTENTIAL FOR MULTIPLY SCATTERED LIGHT IMAGING - A portable, lightweight digital imaging device uses a slit scanning arrangement to obtain an image of the eye, in particular the retina. In at least one embodiment, a digital retinal imaging device includes an illumination source operable to produce a source beam, wherein the source beam defines an illumination pathway, a scanning mechanism operable to cause a scanning motion of the illumination pathway in one dimension with respect to a target, an optical element situated within the illumination pathway, the optical element operable to focus the illumination pathway into an illumination slit at a plane conjugate to the target, wherein the illumination slit is slit shaped, a first two dimensional detector array operable to detect illumination returning from the target and acquire one or more data sets from the detected illumination, wherein the returning illumination defines a detection pathway, and a shaping mechanism positioned within the illumination pathway, wherein the shaping mechanism shapes the source beam into at least one arc at a plane conjugate to the pupil. In at least one exemplary embodiment, the digital retinal imaging device is operable to minimize at least one aberration from the optical element or an unwanted reflection from the target or a reflection from a device. | 05-27-2010 |
| 20100068717 | CANCER THERAPY PROGNOSIS - Methods and compositions based on FOXA1 expression to predict long-term disease-free survival in patients with breast cancer are disclosed. In ER+ positive patients, expression of FOXA1 is useful in identifying a subgroup of patients with a better prognosis. FOXA1 expression correlates with luminal subtype breast cancer, and serves as a clinical marker for luminal subtype breast cancer. Expression of FOXA1 is useful as a prognostic marker for an effective response tumors and as a predictive marker for a greater likelihood of response to an anti-hormonal therapy. Prognostic ability of FOXA1 in low-risk breast cancers is useful in treatment decision making. | 03-18-2010 |
| 20100035297 | METHODS AND COMPOSITIONS FOR VASCULOGENIC POTENTIAL DETERMINATION - Methods and compositions to evaluate the therapeutic vasculogenic potential of a variety of cells including endothelial cells using a monolayer of pericytic cells are disclosed. Pericytic cells or mural cells including those isolated from adipose tissue, such as for example, adipose stromal cells (ASC) or adipose-derived stromal cells (ADSCs) provide suitable conditions that stimulate endothelial cells from different origins to modulate stable vascular network organization in an in vitro experimental setting. Compositions that contain premixed ASC and EC are suitable for testing a candidate agent's angiogenic or antiangiogenic potential. | 02-11-2010 |
| 20090029359 | DIAGNOSTIC METHODS FOR EARLY CANCER DETECTION - The present disclosure is directed to compositions and methods for detecting signs of telomere dysfunction as diagnostic indicators of metastatic disease. More particularly, diagnostic reagents and procedures are provided for analyzing samples to detect elevated expression of TRK2 protein or detect the presence of telomere fusions as an early diagnostic test for cancerous or pre-cancerous cells. In one embodiment the methods of the present disclosure are used to diagnose the existence of, or assess the risk of, breast cancer in an individual. | 01-29-2009 |
| 20090017013 | MOLECULES FOR THE TREATMENT OF LUNG DISEASE INVOLVING AN IMMUNE REACTION TO CONNECTIVE TISSUE FOUND IN THE LUNG - Various embodiments include methods for diagnosing and treating medical conditions that involve an autoimmune response to connective tissue such as collagen found in organs such as the lung. In one method pulmonary disease and disorders such as Idiopathic Pulmonary Fibrosis (IPF) are diagnosed by analyzing fluid or tissue samples obtained from a patient for evidence of an autoimmune response to various types of collagen including, for example, Type V. One type of assay for evidence of an autoimmune response to Type V collagen comprises the steps of obtaining a fluid or tissue sample from a patient, contacting at least a portion of the sample with antigen to anti-Type V collagen antibody and monitoring the mixture of sample and antigen for changes indicative of the presence of anti-Type V collagen in the sample. Another embodiment includes treating pulmonary diseases such as IPF by administering a therapeutically effective dose of epitopes of various collagens including Type V collagen. | 01-15-2009 |
| 20090006001 | EMPIRICAL QUANTITATIVE APPROACHES FOR PSYCHIATRIC DISORDERS PHENOTYPES - Psychiatric phenotypes as currently defined are primarily the result of clinical consensus criteria rather than empirical research. A novel approach to characterizing psychiatric phenotypes is presented herein, termed PhenoChipping. A massive parallel profiling of cognitive and affective state is done with a PhenoChip composed of a battery of existing and new quantitative psychiatric rating scales, as well as hand neuromotor measures. Phenotypic overlap among, as well as phenotypic heterogeneity within, the three major psychotic disorders studied were demonstrated. Empirically derived clusterings of (endo)phenotypes and of patients serve genetic, pharmacological, and imaging research, as well as clinical practice. | 01-01-2009 |
| 20080312418 | Antibody Specific for Human 4-1BB Receptor - The human receptor H4-1BB has been isolated, sequenced and disclosed herein. The cDNA of the human receptor H4-1BB is about 65% homologous to the mouse cDNA 4-1BB and was isolated by using probes derived from cDNA 4-1BB. A fusion protein for detecting cell membrane ligands to human receptor protein H4-1BB was developed. It comprises the extracellular portion of the receptor protein H4-1BB and a detection protein (alkaline phosphatase) bound to the portion of the receptor protein H4-1BB. B-cells that have expressed a ligand to receptor protein H4-1BB can be treated with cells that have expressed receptor protein H4-1BB and B-cell proliferation may be induced. The use of H4-1BB to block H4-1BB ligand binding has practical application in the suppression of the immume system during organ transplantation. A monoclonal antibody against H4-1BB can be used to enhance T-cell proliferation by treating T-cells that have expressed receptor protein H4-1BB with the anti H4-1BB monoclonal antibody. Tumors transfected with H4-1BBL may be capable of delivering antigen-specific signals as well as the co-stimulatory signals and can be killed by human cytotoxic T lymphocytes. | 12-18-2008 |
| 20080293845 | Biodegradable Implant Polymers and Composites - Biodegradable oligomeric polyesters based upon hydroxy acids, such as glycolic acid (GA), lactic acid (LLA), and copolymers thereof are described. Composites that include biodegradable polyesters and bioabsorbable fillers are also described. The described polymers and composites are injectable and in situ curable. | 11-27-2008 |
